[HTML][HTML] Regulatory T cell-mediated control of autoantibody-induced inflammation

K Fujio, T Okamura, S Sumitomo… - Frontiers in …, 2012 - frontiersin.org
K Fujio, T Okamura, S Sumitomo, K Yamamoto
Frontiers in immunology, 2012frontiersin.org
Autoimmune inflammation including autoantibody-induced inflammation is responsible for
the lethal organ damage. Autoantibody-induced inflammation can be separated in two
components, autoantibody production, and local inflammatory responses. Accumulating
evidence has suggested that regulatory T cells (Treg) control both antibody production and
the numbers and functions of effector cells such as innate cells and T helper cells.
Autoantibodies are produced by both the follicular and extrafollicular pathways. Recently …
Autoimmune inflammation including autoantibody-induced inflammation is responsible for the lethal organ damage. Autoantibody-induced inflammation can be separated in two components, autoantibody production, and local inflammatory responses. Accumulating evidence has suggested that regulatory T cells (Treg) control both antibody production and the numbers and functions of effector cells such as innate cells and T helper cells. Autoantibodies are produced by both the follicular and extrafollicular pathways. Recently, follicular regulatory T cells (TFR) and Qa-1 restricted CD8+ Treg were identified as populations that are capable of suppressing follicular T helper cell (TFH)-mediated antibody production. In local inflammation, CD4+CD25+Foxp3+ Treg have the capacity to control inflammation by suppressing cytokine production in T helper cells. Although complement proteins contribute to autoantibody-induced local inflammation by activating innate cells, Treg including CD4+CD25+Foxp3+ Treg are able to suppress innate cells, chiefly via IL-10 production. IL-10-secreting T cells such as T regulatory type I (Tr1) and Tr1-like cells might also play roles in the control of Th17 and innate cells. Therefore, several kinds of Tregs have the potential to control autoimmune inflammation by suppressing both autoantibody production and the local inflammatory responses induced by autoantibodies.
Frontiers